Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in cancer metastasis, cachexia and orphan diseases. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.

Galapagos' service division, which includes BioFocus and the recently acquired service operations from Argenta, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates.

March 5, 2010
Galapagos reports record revenues and net profit for 2009, foresees sustained profitability
View webcast presentation
Read more

February 23, 2010
Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259
Read more

February 22, 2010
Galapagos delivers third candidate drug in GSK alliance, receives €5.7 million
Read more